Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy

102

Transcript of Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy

Page 1: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 2: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 3: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 4: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 5: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 6: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 7: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 8: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 9: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 10: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 11: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 12: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 13: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 14: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 15: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 16: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 17: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 18: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 19: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 20: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 21: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 22: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 23: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 24: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 25: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 26: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 27: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 28: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 29: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 30: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 31: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 32: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 33: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 34: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 35: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 36: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 37: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 38: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 39: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 40: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 41: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 42: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 43: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 44: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 45: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 46: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 47: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 48: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 49: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 50: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 51: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 52: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 53: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 54: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 55: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 56: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 57: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 58: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 59: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 60: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 61: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 62: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 63: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 64: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 65: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 66: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 67: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 68: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 69: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 70: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 71: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 72: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 73: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 74: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 75: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 76: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 77: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 78: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 79: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 80: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 81: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 82: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 83: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 84: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 85: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 86: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 87: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 88: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 89: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 90: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 91: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 92: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 93: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 94: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 95: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 96: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 97: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 98: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 99: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 100: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 101: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy
Page 102: Maximizing Outcomes With Allogeneic HCT in AML: Insight on the Impact of Novel Therapy

Impact of donor type in patients with AML given allogeneic ... › content › ... · Baron et al., Impact of donor type on outcomes with Flu-TBI conditioning for AML 1 1. Impact

Impact of donor type in patients with AML given allogeneic ... › content › ... · Baron et al., Impact of donor type on outcomes with Flu-TBI conditioning for AML 1 1. Impact

The European LeukemiaNet AML Working Party consensus ...lup.lub.lu.se/search/ws/files/1889047/3737313.pdf · Myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT)

The European LeukemiaNet AML Working Party consensus ...lup.lub.lu.se/search/ws/files/1889047/3737313.pdf · Myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT)

Graft vs Host Disease Remains the major cause of treatment related morbidity and mortality in allogeneic HCT. Caused by donor derived alloreactive T cells.

Graft vs Host Disease Remains the major cause of treatment related morbidity and mortality in allogeneic HCT. Caused by donor derived alloreactive T cells.

HCS Series HCL Series HCT Series - Air Energyairenergy.com/files/products/deltech-hcs-hcl-hct-series-sales-brochure.pdf · HCS, HCL and HCT Series Heatless Dryers 2 HCS, HCL and HCT

HCS Series HCL Series HCT Series - Air Energyairenergy.com/files/products/deltech-hcs-hcl-hct-series-sales-brochure.pdf · HCS, HCL and HCT Series Heatless Dryers 2 HCS, HCL and HCT

CIBMTR Analysis of HCT in Older Patients with AML or MDS · Pharmaceuticals LP, ... be the new ER and HER2 of AML. (Ok, ... CIBMTR Analysis of HCT in Older Patients with AML or MDS

CIBMTR Analysis of HCT in Older Patients with AML or MDS · Pharmaceuticals LP, ... be the new ER and HER2 of AML. (Ok, ... CIBMTR Analysis of HCT in Older Patients with AML or MDS

A novel allogeneic off-the-shelf dendritic cell …...In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and

A novel allogeneic off-the-shelf dendritic cell …...In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity rates and

DE EN CZ ES FR GR HU IT NL PL RO RS Nea HCT 24 V & Nea HCT … · 24 V AC / 1A Carga resistiva 24 V HCT* 230 V HCT* 24 V HCT* 230 V HCT L N CO Programador horario externo Carga (actuadores

DE EN CZ ES FR GR HU IT NL PL RO RS Nea HCT 24 V & Nea HCT … · 24 V AC / 1A Carga resistiva 24 V HCT* 230 V HCT* 24 V HCT* 230 V HCT L N CO Programador horario externo Carga (actuadores

HCT AntiHipertensi baru

HCT AntiHipertensi baru

Cellular Therapy & Immunobiology Working Party...The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Cellular Therapy & Immunobiology Working Party...The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies

Sussex HCT Seminars

Sussex HCT Seminars

HCT-1000 7000-2931 B - OKInternational Library/Metcal...7000-2931_B HCT-1000 HCT-1000 User Guide HCT-1000 Betriebsanleitung HCT-1000 Manuel d’utilisation HCT-1000 Manuale dell'utente

HCT-1000 7000-2931 B - OKInternational Library/Metcal...7000-2931_B HCT-1000 HCT-1000 User Guide HCT-1000 Betriebsanleitung HCT-1000 Manuel d’utilisation HCT-1000 Manuale dell'utente

Deck 2, OCT 17, 2019 Dr. Sarantopoulos finalv3€¦ · 17/10/2019  · Allogeneic Stem Cell Transplantation (HCT) Day 0 3 6 12 Month Post-HSCT GVL GVHD Acute GVHD SIRS Chronic GVHD

Deck 2, OCT 17, 2019 Dr. Sarantopoulos finalv3€¦ · 17/10/2019  · Allogeneic Stem Cell Transplantation (HCT) Day 0 3 6 12 Month Post-HSCT GVL GVHD Acute GVHD SIRS Chronic GVHD

Diagnostiek en behandeling van van AML · o Unfit patients (e.g. HCT -CI≥3; SPPB

Diagnostiek en behandeling van van AML · o Unfit patients (e.g. HCT -CI≥3; SPPB

Pditi Lt Eff tPediatric Late EffectsLate Effects in Pediatric HCT Survivors Second Cancers PTLD Vital Organ Function MDS/AML ... Radiation therapy. Clinical Presentation Related to

Pditi Lt Eff tPediatric Late EffectsLate Effects in Pediatric HCT Survivors Second Cancers PTLD Vital Organ Function MDS/AML ... Radiation therapy. Clinical Presentation Related to

Allogeneic Post Transplant Guide

Allogeneic Post Transplant Guide

Infectious diseases in allogeneic haematopoietic stem cell ......Abstract Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical

Infectious diseases in allogeneic haematopoietic stem cell ......Abstract Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical

Allogeneic IgG combined

Allogeneic IgG combined

ALLOGENEIC HCT FOR MYELOFIBROSIS · –Patient selection (DIPSS Int-2 and High-risk) –Choice of conditioning regimen •Barriers to HCT success –Regimen related-toxicities (hepatotoxicity)

ALLOGENEIC HCT FOR MYELOFIBROSIS · –Patient selection (DIPSS Int-2 and High-risk) –Choice of conditioning regimen •Barriers to HCT success –Regimen related-toxicities (hepatotoxicity)

Micardis HCT

Micardis HCT

Allogeneic HSCT in AMLaihemato/AIH/documents... · Allogeneic Immunotherapy platform Conditioning Donor Age Comorbidity CR Relapse Mol CR Ref AML Pre Allo-HSCT Treatments QOL NRM

Allogeneic HSCT in AMLaihemato/AIH/documents... · Allogeneic Immunotherapy platform Conditioning Donor Age Comorbidity CR Relapse Mol CR Ref AML Pre Allo-HSCT Treatments QOL NRM